BPC-157 / TB-500 pen

Why are BPC-157 and TB-500 combined?

Get availability updates

Join the waitlist. We will email you when it opens.

Rebody reusable pen design concept with a clear cartridge chamber, silver dial, and cap beside it.
Pen design concept

Why people ask about it

Two research programs, one finished prescription.

BPC-157 research centers on tissue protection and repair models. TB-500 research centers on actin, cell movement, and wound biology. The combination needs its own clinical rationale because the separate studies do not establish a combined outcome.

Read the full product guide
Two peptide research paths joining in one recovery composition.

Your treatment

Your monthly supply.

Form3 mL cartridge
StrengthBPC-157 3 mg/mL + TB-500 4.5 mg/mL (9 mg / 13.5 mg per 3 mL cartridge)
DirectionsSet by your clinician and printed on the prescription label
SupplySet by your clinician

When orders open

One exact prescription from review through delivery.

  1. 01Tell us about your health

    Share medications, conditions, prior treatment, and the goal for care.

  2. 02A clinician reviews the request

    The review covers the exact formula, package, directions, and product-specific risks.

  3. 03Your prescription ships

    If prescribed, the labeled medication ships with the approved storage and supply instructions.

Clinical review

Questions that belong in the medical visit.

Review injection-site reactions, allergy risk, pregnancy/breastfeeding status, active malignancy, concurrent medications and therapies, and the combined-product rationale.

Injection-site pain, redness, swelling, bruising, or infection can occur with injected medication. The final pharmacy label and clinician directions control use, storage, missed doses, and when to stop.

Clinical review required before prescribing

Questions people ask

Product, evidence, routine, and access.

Why would a clinician consider the combination?

BPC-157 research centers on tissue protection and repair models. TB-500 research centers on actin, cell movement, and wound biology. The combination needs its own clinical rationale because the separate studies do not establish a combined outcome.

What is the BPC-157 / TB-500 pen package?

BPC-157 / TB-500 Injection - 9 mg / 13.5 mg Cartridge. It contains BPC-157 3 mg/mL + TB-500 4.5 mg/mL (9 mg / 13.5 mg per 3 mL cartridge) and provides 1 month of treatment.

Can I order it now?

Not yet. Join the waitlist and we will email you when it opens.

What happens before an order ships?

A licensed clinician reviews the health history, current medications, treatment goals, and product-specific risks. A licensed U.S. pharmacy fills the medication only when prescribed.

Launch updates

Know when the exact offering is ready.

We will send availability and prescription details when ordering opens.

Product updatesDetails by email

Join the BPC-157 / TB-500 pen waitlist.

Get BPC-157 / TB-500 pen availability by email.

Product updates and occasional emails. Unsubscribe anytime.